Increased detection rates of EGFR and KRAS mutations in NSCLC specimens with low tumour cell content by 454 deep sequencing

Detection of activating EGFR mutations in NSCLC is the prerequisite for individualised therapy with receptor tyrosine kinase inhibitors (TKI). In contrast, mutant downstream effector KRAS is associated with TKI resistance. Accordingly, EGFR mutation status is routinely examined in NSCLC specimens, b...

Descripción completa

Detalles Bibliográficos
Autores principales: Moskalev, Evgeny A., Stöhr, Robert, Rieker, Ralf, Hebele, Simone, Fuchs, Florian, Sirbu, Horia, Mastitsky, Sergey E., Boltze, Carsten, König, Helmut, Agaimy, Abbas, Hartmann, Arndt, Haller, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624006/
https://www.ncbi.nlm.nih.gov/pubmed/23468066
http://dx.doi.org/10.1007/s00428-013-1376-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624006/
https://www.ncbi.nlm.nih.gov/pubmed/23468066
http://dx.doi.org/10.1007/s00428-013-1376-6

Ejemplares similares